BMS to Create Oncology Drug Powerhouse With Celgene Acquisition

Drug Industry Daily
A A
Bristol-Myers Squibb’s planned acquisition of Celgene this year will dramatically increase BMS’ position in oncology drugs as it absorbs the New Jersey-based company’s portfolio of existing cancer drugs and promising pipeline products.

To View This Article:

Login

Subscribe To Drug Industry Daily